As a result, whether VEGFR2 is the key pathway involved in low-dose alcohol-induced adverse effects in cirrhosis cannot be ascertained, and further studies are needed to clarify whether targeting the VEGRF2 pathway is a feasible treatment strategy. This evidence concerns the gene KDR and Cirrhosis.